Introduction {#Sec1}
============

Family history has been used to identify women at increased risk of developing breast cancer \[[@CR1]\]. Women at increased breast cancer risk have been subjected to annual mammography for early diagnosis aiming for early treatment with the hope of improving prognosis \[[@CR2]--[@CR5]\]. The two collaborating centres issuing this report initiated clinical activities more than 20 years ago as open prospective trials, referring all women at appropriate risk to undergo annual mammography. Follow up has been actively sought effectively making the study an open prospective observational trial. We have tested all breast cancer kindreds seen throughout these years for *BRCA1/2* mutations \[[@CR6]--[@CR10]\], and we have reported risk for breast cancer in healthy women in breast cancer kindreds without a demonstrable *BRCA1/2* mutation \[[@CR11]\]. Women with two or more close relatives with breast cancer had 4 % risk for breast cancer before 50 years of age. We here report survival when breast cancer was diagnosed prospectively in kindreds without a demonstrable *BRCA1/2* mutation.

Methods {#Sec2}
=======

The series include all cases subjected to annual mammography having increased risk for breast cancer due to family history from the outpatient cancer genetic clinics in Manchester (UK) and Oslo (Norway). The Norwegian series included 4115 patients and was censored in September 2013. The UK series included 9500 patients and was censored in October 2013. Women at increased breast cancer risk from families without a demonstrable *BRCA1/2* mutation were subjected to annual mammography from age 30--35 years onwards. The annual examinations were performed in dedicated breast cancer diagnostic centres. Examination did not routinely include ultrasound, or MRI, although clinical breast examination was carried out in Manchester. However, USS and occasionally MRI were performed with low threshold if indicated by the results of the mammographic examination. Follow-up for diagnosing cancer was from first to last prospectively planned mammography; in Manchester, women were also checked on the local cancer registry for breast cancer within 2 years after last mammography. In this way, none were lost to follow-up. How the Norwegian and Manchester series were ascertained and genetically tested to exclude causative *BRCA1/2* mutations, has previously been described in detail \[[@CR11], [@CR12]\]. In short, (a) all available breast and ovarian cancer cases, (b) and/or obligate carriers in the families and (c) all prospectively diagnosed cases were examined by sequencing and MLPA methods, additionally in Norway---if none such were available---(d) healthy women at risk themselves were tested. All families where one or more persons with causative mutation(s) were found, were excluded from the present study.

In the Norwegian series, women at high and moderate breast cancer risk as described in the previous report \[[@CR11]\] as well as women with a male relative between the breast cancer case and themselves were initially selected. In the UK series, all women at high or moderate risk (lifetime risk of 1 in 6 or higher \[[@CR2], [@CR4]\] based on family history were selected. All cases with breast cancer prior to inclusion or at first prospective mammography were excluded. All breast cancer cases, irrespective of mode of detection, after first prospectively planned mammography were assessed. Survival after first diagnosed breast cancer was calculated, any possible second cancer in any organ was not considered besides for cause of death as described below. Follow-up after cancer included clinical follow-up and continued annual mammography or more frequent according to treatment regimen. In addition, all patients alive according to our medical files when study was censored were checked against population registry for being alive.

The following observations were used for this study: age at diagnosis, age at last follow-up/age at death if dead, tumour size, histopathological grade (grade) scored as low (1), intermediate (2) or high (3), oestrogen receptor (ER) positive (+) or negative (−), carcinoma in situ (CIS)/invasive carcinoma without nodal spread at diagnosis/nodal spread at diagnosis and the cancers were scored as ductal or lobular. Mode of the breast cancer diagnosis was not included as a variable in the present study. Only a few tumours had been tested for HER2 as this was not routine until recently, therefore, HER2 status was not included in the analyses.

Associations between categorised variables were considered by Chi square tests. Differences in distributions for continuous variables were assessed by two-sample *t* tests. Survival was estimated by the Kaplan--Meier algorithm as time from diagnosis to last follow-up/death. Each patient was scored as alive or dead when censored. Causes of death were identified from the medical files and cancer registry (UK) and patients having died of causes other than breast cancer and not having had spread from breast cancer when dying, were censored as alive to derive a disease-specific survival. Univariate and multivariate hazard rates (HR) for death were calculated by using the Cox proportional hazard method.

Ethics {#Sec3}
======

All patients had consented to genetic testing according to national legislation for health care, and all patients had consented to the current research as approved by national ethical committees.

Results {#Sec4}
=======

Two-hundred and forty-one patients were diagnosed to have cancers, 172 (71 %) were screen detected and 69 (29 %) were interval cancers. Of the screen detected cancers, 42 (24 %) were palpable.

Forty-three cases (18 %) had CIS (39 ductal and 4 lobular) and were excluded from further analyses.

Out of 198 cases with infiltrating breast cancer, 194 had been examined once or more after diagnosis and were included in the survival analyses. Mean and median ages at diagnoses were 49.5 and 49.0 years, respectively. They had been observed for a total of 1513 person years, with a mean of 7.6 years and median 7.1 years.

Fifty-four percent of the cases were aged less than 50 years at diagnosis. Eighty-seven percent of the cancers were ductal, 75 % were node negative, 78 % were ER+ and 63 % were grades 1 or 2. Median and mean tumour size at diagnosis was 13 and 15.7 mm, respectively. Nineteen (10 %) had died. See Table [1](#Tab1){ref-type="table"} for details.Table 1Findings in 198 infiltrating breast cancer cases by categorized variablesScoringSubgroupsNumber of cases (% of valid cases) in subgroupType (*n*\* = 193)Ductal168 (87 %)Lobular25 (13 %)Age groups (*n*\* = 198)\<50 years106 (54 %)≥50 years92 (46 %)Nodal status at diagnosis (*n*\* = 197)Node negative147 (75 %)Nodal spread50 (25 %)ER-status (*n*\* = 185)Negative40 (22 %)Positive145 (78 %)Grade (*n*\* = 192)Low38 (20 %)Intermediate83 (43 %)High71 (37 %)Censored (*n*\* = 198)Alive179 (90 %)Dead19 (10 %)Centre (*n*\* = 198)Norway69 (35 %)Manchester129 (65 %)*n*\* number of cases with valid information in selected group

Table [2](#Tab2){ref-type="table"} shows mean tumour sizes and ages at diagnosis, and differences as judged by two-sample *t* tests. Lobular cancers were larger and diagnosed at an earlier age than ductal cancers. Grade 3 tumours were larger than grade 1 tumours (*p* = 0.000), cases with node positive had larger tumours than node negative cases, while there was no difference in size between ER− and ER+ tumours. There was an insignificant trend that those having died had larger tumours at diagnosis than those still alive.Table 2Results of two-sample *t* tests for differences between groupsGroupsMean tumour size (mm)*p*Mean age at diagnosis (years)*p*Ductal14.90.0349.10.007Lobular23.553.2Grade 19.60.00049.50.72Grade 318.449.9Node pos22.10.00049.60.97Node neg13.849.5ER negative17.10.5948.70.57ER positive15.849.5Dead22.00.1248.70.67Alive15.449.6

Survival in different groups is given in Table [3](#Tab3){ref-type="table"}. 5- and 10-years survival in all cases were 93 and 88 %, respectively, and there was no difference in survival between the UK and the Norwegian series (Fig. [1](#Fig1){ref-type="fig"}). Survival in ductal and lobular cases was similar. Survival was similar in patients aged less than 50 versus more than 50 years at diagnosis (Fig. [2](#Fig2){ref-type="fig"}). No case with a grade 1 tumour had died. Cases with ER+ grade 2 tumours also had good prognosis. Eighty-two percent had grade 1 or grade 2 or ER+ tumours and as a combined group had 92 % 10-years survival. ER−, and N+ (Fig. [3](#Fig3){ref-type="fig"}) and Grade 3 (Fig. [4](#Fig4){ref-type="fig"}) were associated with a higher likelihood of death (*p* = 0.000). ER− tumours were associated with increased mortality even when node negative cases were considered separately (Fig. [5](#Fig5){ref-type="fig"}), while tumour grade was not significantly associated with death in node negative cases (Fig. [6](#Fig6){ref-type="fig"}).Table 3Survival in different groups and results of Mantel tests for differences between groupsSelectionSubgroupsNumber of cases included5 years survival (95 % CI)10 years survival (95 % CI)*p*AllAll19493 **%** (88--96)88 **%** (81--92)Norway6994 **%** (85--98)90 **%** (78--95)0.85Manchester12592 **%** (84--96)88 **%** (79--93)\<50 years10395 **%** (87--98)88 **%** (77--94)0.8050 + years9191 **%** (82--95)87 **%** (77--93)Ductal16593 % (87--96)89 % (81--93)0.33Lobular2491 % (66--98)85 % (60--95)ER neg4074 % (56--86)67 % (52--83)0.000ER pos14298 % (93--99)93 % (85-97)Grade 138100 %100 %0.000Grade 28196 % (87--99)96 % (87--99)Grade 36985 % (72--92)72 % (57--83)N−14396 % (91--98)94 % (88--97)0.000N+5083 % (67--91)69 % (51--82)Grade 1, Grade 2 or ER+16096 % (91--99)92 % (85--96)N−Grade 138100 %100 %0.11Grade 26496 % (86--99)96 % (86--99)Grade 33891 % (75--97)87 % (69--95)ER pos107100 %99 % (91--100)0.000ER neg2679 % (57--91)74 % (50--87)Grade 3 and ER−3173 % (51--86)63 % (40--79)N + and ER−1363 % (29--85)53 % (20--77)N + and Grade 3 and ER−1155 % (18--81)41 % (10--71) Fig. 1Survival by country Fig. 2Survival by age at diagnosis Fig. 3Survival by nodal status at diagnosis *p* = 0.000 Fig. 4Survival by tumour grade *p* = 0.000 Fig. 5*Selection* node negative survival by ER receptor status *p* = 0.000 Fig. 6*Selection* node negative survival by tumour grade *p* = 0.11

Grade and nodal status were highly associated (*p* = 0.000), but ER and nodal status at diagnosis were *not* associated, *p* = 0.25 (Table [4](#Tab4){ref-type="table"}).Table 4Nodal status at diagnosis versus tumour receptor status and gradeNode negativeNode positive*p*ER−26130.25ER+11035Grade 13800.000Grade 26617Grade 34030

By univariate Cox proportional hazard, ER, grade and nodal status were associated with death, while age at diagnosis and tumour size at diagnosis were not associated with death (Table [5](#Tab5){ref-type="table"}).Table 5Results univariate Cox proportional hazard for deathNumber of casesNumber of deathsHR (95 % CI)*p* valuelog-rank *p* valueAge 25--4994710.425 50+81101.48 (0.56--3.89)0.428Size 0.1--1.0 cm63410.147 1.1--2.0 cm7261.28 (0.36--4.55)0.700 2.1--7.0 cm4072.89 (0.85--9.86)0.091ER Negative (1)381010.00016 Positive (3)13770.19 (0.07--0.50)0.001Grade Low\* or intermediate108310.00006 High67148.38 (2.41--29.18)0.001Nodal status Negative130610.00004 Positive45116.28 (2.32--17.01)0.0003\* No death in cases with low grade

By multivariate Cox proportional hazard ER, grade and nodal status were associated with increased mortality while age and size were not (Table [6](#Tab6){ref-type="table"}).Table 6Results multivariate Cox proportional hazard for deathNumber of casesHR (95 % CI)*p* valueAge 25--49941 50+812.45 (0.88--6.81)0.086Size 0.1--1.0 cm631 1.1--2.0 cm720.59 (0.15--2.25)0.438 2.1--7.0 cm401.23 (0.30--5.09)0.772ER Negative381 Positive1370.25 (0.09--0.71)0.009Grade Low\* or intermediate1081 High674.42 (1.18--16.56)0.027Nodal status Negative1301 Positive454.08 (1.28--13.06)0.018\* No death in cases with low grade

Discussion {#Sec5}
==========

Overall 10-year survival in initially healthy women from *BRCA1/2* negative familial breast cancer families, who had prospectively detected cancers when subjected to annual mammography, was 88 %. These results add to our previous report that women in such kindreds had about twice the population risk of breast cancer, and may be used for genetic counselling. Considering the previous and the current findings together, the risk of developing a breast cancer before 50 years of age was about 2 %, which multiplied by a 12 % risk of dying from that breast cancer within 10 years, when subjected to annual Mx from 30 years of age, gives a combined risk of less than 1 % to contract an early breast cancer causing death within 10 years. Or---vice versa---the probability to not have an early breast cancer causing death within 10 years was \>99 %. These were our combined empirical observations in patients from breast cancer kindreds without demonstrable *BRCA* mutations subjected to annual mammography from 30 years of age and with current breast cancer treatment. These data could be used for genetic counselling of women at moderate breast cancer risk.

With the increasing availability and reduced cost of genetic testing, one may consider testing a healthy woman with a family history of breast cancer directly and not---as has been done so far---test affected relatives initially. If doing so, the question of risk for breast cancer in *BRCA1/2* carrying kindreds in women not having the family's *BRCA* mutation will become an issue to clarify \[[@CR13]\], as will the biology of such breast cancers. There is a possibility that some families with highly penetrant *BRCA1/2* mutations may have additional (genetic) factors causing breast cancer (independently or modifiers of *BRCA1/2* penetrance). Studies are ongoing to address this.

We have reported the outcome of our health service as applied since the start of the activity. The scope of our study was survival from breast cancer in those accepting our offer of annual mammography from 30 years onwards and current treatment once cancer was diagnosed. The examinations were part of the health care system, and both patient compliance and capacity problems in the diagnostic outpatient clinics might have postponed some examinations for some time. We did not focus on screen-detected versus interval cancers (which anyway is difficult when some patients because of the frequent examinations felt a lump but did not inform us until the next scheduled mammography). If considering details on time between examination, screen-detected versus interval cancers, and compared those with tumour characteristics such as grade, ER, nodal status and size, the strata would be too many for meaningful calculations in our limited series. The results were that most patients in this highly selected series had low grade and/or ER+ tumours which was associated with very good survival. Survival was so good that stratification of this group with respect to survival is of little interest. In contrast, two infrequent subgroups (ER− and high grade) had worse outcome, and numbers did not allow meaningful substratification of these two groups. These patients are now being subjected to sequencing for many more genes known to be associated with breast cancer in search of biological causative factors.

Surprisingly, young age at diagnosis was not associated with worse survival as has been previously published for unscreened women \[[@CR14], [@CR15]\] (Figure [2](#Fig2){ref-type="fig"}). We were not able to conduct a direct comparison with similar family history positive women not undergoing intensive mammography screening. However, it is of note that the 88 % 10-year survival for invasive breast cancer compares favourably to the 71.5 % 10-year survival for all women in the UK diagnosed in 2000--2001 \[[@CR16]\] approximating to the median age at diagnosis in our report. Survival in unscreened family history positive women diagnosed with breast cancer in the UK under 40 years of age between 2000 and 2008 was poor in a recent study with only 70 % being alive without metastasis at a mean of 7-year follow-up \[[@CR16]\] and with 8-year overall survival of only 67.3 % for all women \[[@CR15]\]. Also, 10 year survival was better in the group described here than in inherited breast cancer caused by *BRCA1* mutations \[[@CR17]\].

The associations between the findings lead us to the following speculations {#Sec6}
===========================================================================

A small proportion of the cases had grade 3 and/or ER− and/or were node positive and carried a worse prognosis, but ER− and node positive were not associated with each other. It is interesting that the effect on mortality on having a tumour an ER− tumour and being node positive, was additive (Table [3](#Tab3){ref-type="table"}). Numbers included were, however, limited, and we look forward to see results from other centres on this specific issue.

Conclusions {#Sec7}
===========

In women at increased familial breast cancer risk without a demonstrable *BRCA1/2* mutation, the overall chances of developing breast cancer causing death within 10 years before 50 years of age was less than 1 % when subjected to annual mammography and current treatment. The majority of patients had ER+ and/or grade 1 or 2 tumours, and survived. A minor fraction of the patient had ER− tumours and/or nodal spread at diagnosis, both of which were associated with worse prognosis but ER+ and nodal spread at diagnosis were not associated. The results to us indicated that annual mammography from 30 years of age should be continued while the search for more genes that cause inherited breast cancer continues \[[@CR18]\]. Hopefully, one may arrive at understanding why some patients have worse prognosis and develop more effective personalised preventive and/or treatment modalities.
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